>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance:

CBMX +19.5%, CPG +14.3%, UCTT +12.1%, TGB +10.7%, CRI +9.5%, SQ +9%, SBGL +7.8%, SPAR +7.8%, DOOR +6.6%, TRNC +5.8%, DNR +5.8%
CTRP +5.1%, OAS +4.7%, CRZO +3.8%, VC +3.7%, RIG +3.4%,COTV +3.3%, IAG +3.2%, OCN +2.8%, HL +2.8%, GDOT +2.7%,ZBRA +2.6%, TEF +2.5%
RGR +2.4%, CHK +2.4%, KSS +2.4%, WPX +2.3%, SXL +2.2%, HPQ +1.9%, ETP +1.8%, RRC +1.7%, SAIC +1.7%, PRAH +1.4%, DMRC +1.4%, CNK +1.4%
CLR +1.2%, LTC +1.1%, TFX +1.1%, VALE +1.1%, APA +1.1%,TCAP +1%, JAKK +1%, MYGN +1%

Select metals/mining stocks trading higher:

IAG +3.2%, AUY +2.5%, AU +2.4%, AG +1.5%, BBL +1.2%, SLW+1%, BHP +0.8%

Select oil/gas related names showing strength:

SDRL +3.4%, NOV +2.3%, PBR +1.9%, MRO +1.5%, COP +1.4%,HES +1.3%, BP +1.2%, KMI +1.2%, HAL +1.1%

Other news:

PTX +40.1% (receives a favorable opinion in its litigation with Actavis Laboratories FL, Inc. regarding a proposed generic version of Zohydro ER)
NAK +33.1% (rebounding from yesterday's move lower; comments on US House Committee on Science, Space and Technology letter to EPA Administrator to withdraw Pebble Project veto)
AVEO +19.2% (Phase 3 TIVO-3 trial to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma has successfully completed the first safety review by the study's Safety Monitoring Committee)
URRE +12.6% (reports 'favorable' lithium concentrations at the Columbus Basin Project )
INO +7.6% (presents positive clinical data on Inovio's DNA-based vaccines against MERS)
ASPS +4.5% (continued strength after the CEO disclosed purchase of 5,250 shares)
TRXC +3.1% (launched commercial operations and completed its first sale of the Senhance Surgical System in Germany)
FNMA +2.3% (Fairholme provides update on Fannie Mae and Freddie Mac)
MT +2% (ArcelorMittal Brasil and Votorantim sign agreement to combine their Brazilian long steel businesses)
FMCC +1.4% (Fairholme provides update on Fannie Mae and Freddie Mac)
SHPG +1.4% (publication of results from the Phase 1b study of lanadelumab in NEJM)
NTES +1.2% (following SINA results)
TIF +1% (JANA Partners filed a 13D confirming its 4.9% active stake)

Analyst comments: